FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
(NASDAQ: FRNM) Delayed: 17.11 +0.82 (5.03%)
Previous Close $16.29    52 Week High $ 
Open $16.35    52 Week Low $ 
Day High $17.26    P/E N/A 
Day Low $16.27    EPS $ 
Volume 6,047,306